{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/abbvie-abbv/",
 "dataUrl": "https://clearank.com/stock/abbvie-abbv/data.json",
 "title": "AbbVie (ABBV) Stock Forecast & Price Target (2026)",
 "description": "AbbVie Inc. (ABBV) stock: Healthcare, Drug Manufacturers - General. $467.1B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "AbbVie Inc. (ABBV)",
 "published": "2026-06-14T09:12:01+00:00",
 "modified": "2026-09-27T12:16:47.868+00:00",
 "generated": "2026-09-27T15:53:28.169Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "ABBV",
  "name": "AbbVie Inc.",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Drug Manufacturers - General",
  "country": "United States",
  "website": "https://www.abbvie.com"
 },
 "quote": {
  "price": 264.34,
  "previousClose": 265.12,
  "change": -0.78,
  "changePercent": -0.29,
  "open": 265.48999,
  "high": 266,
  "low": 262.59,
  "volume": 2540400,
  "averageVolume": 4009700,
  "marketCap": 467119783116,
  "fiftyTwoWeekHigh": 269.39001,
  "fiftyTwoWeekLow": 190.75,
  "marketOpen": false,
  "asOf": "2026-09-27T12:16:47.000Z"
 },
 "statistics": {
  "pe": 74.461975,
  "eps": 3.55,
  "dividendYield": 0.026181378169268587,
  "beta": 0.281,
  "priceToSales": 7.2549896,
  "priceToBook": -79.32304302767935,
  "revenueTtm": 64385998848,
  "grossMargin": 0.7474396703943497,
  "returnOnEquity": -1.2967781908302354
 },
 "technicals": {
  "rsi": 65.02,
  "macd": 2.61,
  "sma50": 257.05,
  "sma200": 230.56,
  "rsiSignal": "Bullish",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Buy",
  "score": 75,
  "consensus": "Buy",
  "fairValue": 283.5,
  "analystTarget": 283.5,
  "analystCount": 30,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-27T12:16:47.000Z",
  "priceAtAnalysis": 264.34,
  "volatility": {
   "daily": 1.31,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bullish",
  "conservativeEntry": 259.05,
  "aggressiveEntry": 264.34,
  "stopLoss": 251.28,
  "stopLossPercent": 3,
  "targets": [
   272.01,
   284.96,
   297.91
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 209.38,
    "base": 293.31,
    "upside90th": 410.89
   },
   {
    "year": 2028,
    "downside10th": 202.05,
    "base": 325.45,
    "upside90th": 524.23
   },
   {
    "year": 2029,
    "downside10th": 201.41,
    "base": 361.12,
    "upside90th": 647.47
   },
   {
    "year": 2030,
    "downside10th": 204.18,
    "base": 400.7,
    "upside90th": 786.33
   },
   {
    "year": 2031,
    "downside10th": 209.23,
    "base": 444.61,
    "upside90th": 944.77
   },
   {
    "year": 2032,
    "downside10th": 216.05,
    "base": 493.33,
    "upside90th": 1126.51
   },
   {
    "year": 2033,
    "downside10th": 224.38,
    "base": 547.4,
    "upside90th": 1335.46
   },
   {
    "year": 2034,
    "downside10th": 234.1,
    "base": 607.39,
    "upside90th": 1575.93
   },
   {
    "year": 2035,
    "downside10th": 245.16,
    "base": 673.95,
    "upside90th": 1852.75
   },
   {
    "year": 2036,
    "downside10th": 257.54,
    "base": 747.81,
    "upside90th": 2171.38
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "ABBV Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$265.49",
    "Day Range": "$262.59 to $266.00",
    "Prev Close": "$265.12",
    "Volume": "2.54M",
    "52-Week Range": "$190.75 to $269.39",
    "Market Cap": "$467.12B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Trading at a significant premium to sector peers (+133%), suggesting market expectations for superior growth or market position."
   ]
  },
  {
   "id": "financials",
   "title": "ABBV Financial Performance",
   "text": [
    "Analysis: In the last 4 quarters, ABBV beat estimates 3 times. The stock rose 2 times the next day. Price tends to react positively to beats."
   ]
  },
  {
   "id": "analysis",
   "title": "ABBV Analysis",
   "text": [
    "At $264.34, AbbVie Inc. is trading above its 50-day SMA of $257.05 and its 200-day SMA of $230.56, signaling a bullish trend. The Relative Strength Index (RSI) is at 65.02, indicating bullish momentum without being overbought. Key support levels are near the 50-day SMA, while resistance is implied by the median analyst target price of $283.5. Volume has been below average recently, suggesting a lack of strong conviction behind the current price action. The chart structure indicates continued upward potential, provided key support levels hold.",
    "Analysts project significant EPS and revenue growth for the current and next year, providing a fundamental basis for continued stock appreciation.",
    "The stock is trading above key moving averages (50-day and 200-day SMA) with a bullish RSI, indicating favorable short-to-medium term price action.",
    "AbbVie's P/E and Price-to-Sales ratios are substantially higher than sector averages, creating risk if growth falters.",
    "Significant insider selling totaling $42.3 million across 44 transactions suggests a lack of immediate buying conviction from management.",
    "AbbVie Inc. is expected to continue its growth trajectory, driven by strong forward earnings and revenue estimates. The median analyst target price of $283.5 suggests a modest upside from the current trading level, supported by positive technical indicators and a solid operational margin. However, the company's premium valuation and negative return on equity present potential headwinds. Any significant slowdown in growth or a shift in market sentiment towards value stocks could pressure the stock. Investors should monitor upcoming earnings reports and pipeline developments closely."
   ],
   "lists": {
    "ProTips": [
     "Monitor insider selling trends closely, as a significant increase could signal waning management confidence.",
     "Given the stock is trading above its 50-day and 200-day moving averages ($257.05 and $230.56), consider using these levels as potential support zones for entry or stop-loss points.",
     "The company's high P/E ratio relative to its sector suggests that future growth must meet or exceed expectations to justify the current valuation."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Strong Forward Growth Estimates",
     "text": "Analysts project significant EPS and revenue growth for the current and next year, providing a fundamental basis for continued stock appreciation.",
     "source": "Wall Street Estimates"
    },
    {
     "type": "Bullish",
     "title": "Positive Technical Momentum",
     "text": "The stock is trading above key moving averages (50-day and 200-day SMA) with a bullish RSI, indicating favorable short-to-medium term price action.",
     "source": "Technical Analysis"
    },
    {
     "type": "Bearish",
     "title": "Elevated Valuation Metrics",
     "text": "AbbVie's P/E and Price-to-Sales ratios are substantially higher than sector averages, creating risk if growth falters.",
     "source": "Fundamental Analysis"
    },
    {
     "type": "Bearish",
     "title": "Moderate Insider Selling",
     "text": "Significant insider selling totaling $42.3 million across 44 transactions suggests a lack of immediate buying conviction from management.",
     "source": "Insider Transactions"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "AbbVie Inc. (ABBV) trades at a P/E ratio of 74.46, significantly above the Healthcare sector median of 31.9, and its price-to-sales ratio of 7.25 is also elevated compared to the sector average of 3.7. Despite this premium valuation, the company boasts strong operational efficiency with a 40.04% operating margin and a 9.80% net profit margin. The company's balance sheet shows a negative debt-to-equity ratio of -0.12, indicating minimal leverage. However, the return on equity is a concerning -129.68%. The forward growth estimates, with projected EPS growth of 40.1% for the current year and 16.1% for the next, are critical in justifying the current valuation multiples.",
    "AbbVie Inc. most recently reported earnings for the quarter ending June 2026, with an actual EPS of $3.65, beating the estimate of $3.61 by 1.11%. This followed a slight miss in the prior quarter. The company has shown a mixed pattern of beating and missing estimates in recent quarters, but the overall trend in EPS estimates for the current and next year remains strong, with projected growth of 40.1% and 16.1% respectively.",
    "A primary risk for AbbVie Inc. is its elevated valuation, with a P/E ratio significantly higher than its sector peers, which could lead to a sharp correction if growth expectations are not met. Moderate insider selling, with $42.3 million in sales across 44 transactions, warrants attention as it may signal a lack of immediate conviction from management. Also, the negative return on equity of -129.68% raises concerns about the company's ability to generate profits from its equity base. While forward growth estimates are strong, any deceleration could put pressure on the current stock price."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "467.12B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "74.46"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "3.55"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "2.58%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "269.39"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "190.75"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Bullish SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($257.05) above the 200-day SMA ($230.56), price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Bullish",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "65.02"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "2.61"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "257.05"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "230.56"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.16",
    "Correlation with Nasdaq 100 (QQQ)": "+0.04",
    "Correlation with Bitcoin (BTC)": "-0.11",
    "Correlation with Gold (XAU)": "+0.02"
   }
  },
  {
   "id": "trade-plans",
   "title": "ABBV Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for pullback",
    "Higher risk, immediate entry",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (65.0) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$272.01",
    "TARGET 2": "$284.96",
    "TARGET 3": "$297.91",
    "STOP LOSS": "$251.28"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "-1.57%",
    "Average Feb return": "+3.97%",
    "Average Mar return": "-2.07%",
    "Average Apr return": "-1.27%",
    "Average May return": "-0.52%",
    "Average Jun return": "+3.83%",
    "Average Jul return": "-0.38%",
    "Average Aug return": "+2.16%",
    "Average Sep return": "+2.98%",
    "Average Oct return": "-2.48%",
    "Average Nov return": "+6.33%",
    "Average Dec return": "+3.35%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.31%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in ABBV in September 2016 would be worth about $40,939 today, compared with about $35,782 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in ABBV today could grow to about $28,290 by 2036 in the base case, with a bull case near $82,143 and a bear case around $9,743. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "ABBV Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $401 for ABBV by 2030 in the base case, from $264 today (1.5x over 4 years). The downside path ends near $204. These are outcomes of a Monte Carlo simulation run on ABBV's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using ABBV's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "ABBV simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$209",
        "$293",
        "$411"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$202",
        "$325",
        "$524"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$201",
        "$361",
        "$647"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$204",
        "$401",
        "$786"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$209",
        "$445",
        "$945"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$216",
        "$493",
        "$1,127"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$224",
        "$547",
        "$1,335"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$234",
        "$607",
        "$1,576"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$245",
        "$674",
        "$1,853"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$258",
        "$748",
        "$2,171"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "CI The Cigna Group NYSE $272.01 +2.45%",
     "url": "https://clearank.com/stock/cigna-group-ci/"
    },
    {
     "text": "LEGN Legend Biotech Corporation NASDAQ $19.11 +0.26%",
     "url": "https://clearank.com/stock/legend-biotech-legn/"
    },
    {
     "text": "TMO Thermo Fisher Scientific Inc. NYSE $675.00 -0.50%",
     "url": "https://clearank.com/stock/tmo-stock-analysis/"
    },
    {
     "text": "HIMS Hims & Hers Health, Inc. NYSE $29.42 +0.48%",
     "url": "https://clearank.com/stock/hims-hers-health-hims/"
    },
    {
     "text": "NEOG Neogen Corp. NASDAQ $13.76 +0.73%",
     "url": "https://clearank.com/stock/neogen-neog/"
    },
    {
     "text": "CRSP CRISPR Therapeutics AG NASDAQ $54.23 -2.64%",
     "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
    },
    {
     "text": "OFIX Orthofix Medical Inc. NASDAQ $9.44 +3.06%",
     "url": "https://clearank.com/stock/ofix-stock-analysis/"
    },
    {
     "text": "IQV IQVIA Holdings Inc. NYSE $270.37 -1.69%",
     "url": "https://clearank.com/stock/iqvia-iqv/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Compare ABBV",
   "links": [
    {
     "text": "LLY vs ABBV Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/lly-vs-abbv/"
    },
    {
     "text": "CSX vs NSC Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/csx-vs-nsc/"
    },
    {
     "text": "XAG/USD vs XPT/USD Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/silver-vs-platinum/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "ABBV Insider Trading Analysis",
   "facts": {
    "Bought": "None",
    "Sold": "$42.3M",
    "Insiders": "23",
    "Avg Transaction": "$6.0M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in ABBV",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Apr 28, 2020",
       "cells": [
        "Norges Bank Investment Management",
        "Sell",
        "1.1M",
        "$88.2M"
       ]
      },
      {
       "label": "Jul 17, 2024",
       "cells": [
        "GONZALEZ RICHARD A Officer and Director",
        "Sell",
        "282.8K",
        "$49.5M"
       ]
      },
      {
       "label": "May 10, 2022",
       "cells": [
        "SEVERINO MICHAEL E Officer",
        "Sell",
        "300.0K",
        "$45.3M"
       ]
      },
      {
       "label": "May 17, 2022",
       "cells": [
        "SEVERINO MICHAEL E Officer",
        "Sell",
        "200.0K",
        "$30.8M"
       ]
      },
      {
       "label": "Feb 28, 2024",
       "cells": [
        "GONZALEZ RICHARD A Chief Executive Officer",
        "Sell",
        "138.6K",
        "$24.6M"
       ]
      },
      {
       "label": "Dec 17, 2021",
       "cells": [
        "SCHUMACHER LAURA J Officer",
        "Sell",
        "181.7K",
        "$23.7M"
       ]
      },
      {
       "label": "Nov 12, 2020",
       "cells": [
        "GONZALEZ RICHARD A Chief Executive Officer",
        "Sell",
        "231.6K",
        "$22.4M"
       ]
      },
      {
       "label": "Dec 9, 2021",
       "cells": [
        "GONZALEZ RICHARD A Chief Executive Officer",
        "Sell",
        "174.1K",
        "$21.5M"
       ]
      },
      {
       "label": "Apr 21, 2020",
       "cells": [
        "Norges Bank Investment Management",
        "Sell",
        "259.0K",
        "$20.8M"
       ]
      },
      {
       "label": "Mar 3, 2025",
       "cells": [
        "GONZALEZ RICHARD A Director",
        "Sell",
        "98.6K",
        "$20.3M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=AbbVie+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is AbbVie Inc.'s stock price forecast for 2030?",
   "answer": "Based on a Monte Carlo simulation, AbbVie Inc.'s stock price is projected to be $400.7 in 2030 under a base case scenario. The downside projection is $204.18, and the upside projection is $786.33. These are statistical outcomes, not guarantees."
  },
  {
   "question": "Is AbbVie Inc. stock a buy right now?",
   "answer": "AbbVie Inc. is currently rated a Buy with a consensus score of 75. The stock is trading above key moving averages, and Wall Street analysts have a median price target of $283.5, suggesting a modest upside."
  },
  {
   "question": "What are the key technical indicators for AbbVie Inc.?",
   "answer": "AbbVie Inc. is trading above its 50-day and 200-day moving averages ($257.05 and $230.56), indicating a bullish trend. The RSI is at 65.02, showing bullish momentum, and the MACD is positive at 2.61."
  },
  {
   "question": "How does AbbVie Inc.'s valuation compare to its sector peers?",
   "answer": "AbbVie Inc.'s P/E ratio of 74.46 and price-to-sales ratio of 7.25 are significantly higher than the Healthcare sector medians of 31.9 and 3.7, respectively, suggesting it trades at a premium."
  },
  {
   "question": "What is the recent insider trading activity for AbbVie Inc.?",
   "answer": "Insiders at AbbVie Inc. are net sellers, with $42.3 million in total sales in recent filings and no reported purchases. This indicates a moderate sell signal from management."
  },
  {
   "question": "What are the forward earnings and revenue growth estimates for AbbVie Inc.?",
   "answer": "Analysts project AbbVie Inc.'s EPS to grow by 40.1% in the current year and 16.1% next year. Revenue is expected to increase by 11.00% this year and 9.00% next year."
  },
  {
   "question": "What are the main risks facing AbbVie Inc.?",
   "answer": "Key risks include its high valuation relative to peers, a negative return on equity, and moderate insider selling. Any failure to meet aggressive growth expectations could negatively impact the stock price."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "CI",
    "name": "The Cigna Group NYSE",
    "price": "$272.01",
    "change": "+2.45%",
    "url": "https://clearank.com/stock/cigna-group-ci/"
   },
   {
    "ticker": "LEGN",
    "name": "Legend Biotech Corporation NASDAQ",
    "price": "$19.11",
    "change": "+0.26%",
    "url": "https://clearank.com/stock/legend-biotech-legn/"
   },
   {
    "ticker": "TMO",
    "name": "Thermo Fisher Scientific Inc. NYSE",
    "price": "$675.00",
    "change": "-0.50%",
    "url": "https://clearank.com/stock/tmo-stock-analysis/"
   },
   {
    "ticker": "HIMS",
    "name": "Hims & Hers Health, Inc. NYSE",
    "price": "$29.42",
    "change": "+0.48%",
    "url": "https://clearank.com/stock/hims-hers-health-hims/"
   },
   {
    "ticker": "NEOG",
    "name": "Neogen Corp. NASDAQ",
    "price": "$13.76",
    "change": "+0.73%",
    "url": "https://clearank.com/stock/neogen-neog/"
   },
   {
    "ticker": "CRSP",
    "name": "CRISPR Therapeutics AG NASDAQ",
    "price": "$54.23",
    "change": "-2.64%",
    "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
   },
   {
    "ticker": "OFIX",
    "name": "Orthofix Medical Inc. NASDAQ",
    "price": "$9.44",
    "change": "+3.06%",
    "url": "https://clearank.com/stock/ofix-stock-analysis/"
   },
   {
    "ticker": "IQV",
    "name": "IQVIA Holdings Inc. NYSE",
    "price": "$270.37",
    "change": "-1.69%",
    "url": "https://clearank.com/stock/iqvia-iqv/"
   }
  ],
  "comparisons": [
   {
    "ticker": "LLY vs ABBV Comparison",
    "name": "",
    "url": "https://clearank.com/compare/lly-vs-abbv/"
   },
   {
    "ticker": "CSX vs NSC Comparison",
    "name": "",
    "url": "https://clearank.com/compare/csx-vs-nsc/"
   },
   {
    "ticker": "XAG/USD vs XPT/USD Comparison",
    "name": "",
    "url": "https://clearank.com/compare/silver-vs-platinum/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "CCI",
    "text": "Crown Castle Inc.",
    "url": "https://clearank.com/stock/cci-stock-analysis/"
   },
   {
    "ticker": "AME",
    "text": "AMETEK Inc",
    "url": "https://clearank.com/stock/ame-stock-analysis/"
   },
   {
    "ticker": "VRSK",
    "text": "Verisk Analytics, Inc.",
    "url": "https://clearank.com/stock/vrsk-stock-analysis/"
   },
   {
    "ticker": "DEO",
    "text": "Diageo plc Sponsored",
    "url": "https://clearank.com/stock/deo-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "CRDO",
    "text": "↑ 7.65%",
    "url": "https://clearank.com/stock/credo-crdo/"
   },
   {
    "ticker": "BLNE",
    "text": "↓ 7.40%",
    "url": "https://clearank.com/stock/blne-beeline-holdings/"
   },
   {
    "ticker": "GRT/USD",
    "text": "↑ 20.82%",
    "url": "https://clearank.com/crypto/the-graph-grt/"
   },
   {
    "ticker": "SEI/USD",
    "text": "↑ 19.29%",
    "url": "https://clearank.com/crypto/sei-sei/"
   },
   {
    "ticker": "WLD/USD",
    "text": "↑ 17.41%",
    "url": "https://clearank.com/crypto/worldcoin-wld/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "AMGN",
    "text": "Amgen",
    "url": "https://clearank.com/stock/amgen-amgn/"
   },
   {
    "ticker": "BIIB",
    "text": "Biogen Inc.",
    "url": "https://clearank.com/stock/biib-stock-analysis/"
   },
   {
    "ticker": "BMY",
    "text": "Bristol-Myers Squibb",
    "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/"
   },
   {
    "ticker": "GILD",
    "text": "Gilead Sciences",
    "url": "https://clearank.com/stock/gilead-sciences-gild/"
   },
   {
    "ticker": "JNJ",
    "text": "Johnson & Johnson",
    "url": "https://clearank.com/stock/johnson-johnson-jnj/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/06/abbv.png",
     "url": "https://clearank.com/wp-content/uploads/2026/06/abbv.png",
     "width": "1280",
     "height": "720",
     "caption": "AbbVie (ABBV) stock price analysis chart for June 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/abbvie-abbv/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/abbvie-abbv/",
        "name": "AbbVie (ABBV) Stock Price Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/abbvie-abbv/#webpage",
     "url": "https://clearank.com/stock/abbvie-abbv/",
     "name": "AbbVie (ABBV) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-06-14T09:12:01+00:00",
     "dateModified": "2026-09-27T12:16:47+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/abbv.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/abbvie-abbv/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/abbvie-abbv/#richSnippet",
     "headline": "AbbVie (ABBV) Stock Forecast & Price Target (2026)",
     "name": "AbbVie (ABBV) Stock Forecast & Price Target (2026)",
     "description": "AbbVie Inc. (ABBV) stock: Healthcare, Drug Manufacturers - General. $467.1B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-06-14T09:12:01+00:00",
     "dateModified": "2026-09-27T12:16:47+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "AbbVie Inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "ABBV"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NYSE"
       }
      ],
      "description": "AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies for complex and serious diseases. AbbVie focuses on major therapeutic areas including immunology, oncology, neuroscience, eye care, aesthetics, and virology, serving patients wit",
      "tickerSymbol": "ABBV",
      "sameAs": "https://www.abbvie.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/abbvie-abbv/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/abbv.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/abbvie-abbv/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is AbbVie Inc.'s stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on a Monte Carlo simulation, AbbVie Inc.'s stock price is projected to be $400.7 in 2030 under a base case scenario. The downside projection is $204.18, and the upside projection is $786.33. These are statistical outcomes, not guarantees."
     }
    },
    {
     "@type": "Question",
     "name": "Is AbbVie Inc. stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "AbbVie Inc. is currently rated a Buy with a consensus score of 75. The stock is trading above key moving averages, and Wall Street analysts have a median price target of $283.5, suggesting a modest upside."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key technical indicators for AbbVie Inc.?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "AbbVie Inc. is trading above its 50-day and 200-day SMAs, indicating a bullish trend. The RSI is at 65.02, showing bullish momentum, and the MACD is positive at 2.61."
     }
    },
    {
     "@type": "Question",
     "name": "How does AbbVie Inc.'s valuation compare to its sector peers?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "AbbVie Inc.'s P/E ratio of 74.46 and price-to-sales ratio of 7.25 are significantly higher than the Healthcare sector medians of 31.9 and 3.7, respectively, suggesting it trades at a premium."
     }
    },
    {
     "@type": "Question",
     "name": "What is the recent insider trading activity for AbbVie Inc.?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Insiders at AbbVie Inc. are net sellers, with $42.3 million in total sales across 44 transactions and no reported purchases. This indicates a moderate sell signal from management."
     }
    },
    {
     "@type": "Question",
     "name": "What are the forward earnings and revenue growth estimates for AbbVie Inc.?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Analysts project AbbVie Inc.'s EPS to grow by 40.1% in the current year and 16.1% next year. Revenue is expected to increase by 11.00% this year and 9.00% next year."
     }
    },
    {
     "@type": "Question",
     "name": "What are the main risks facing AbbVie Inc.?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Key risks include its high valuation relative to peers, a negative return on equity, and moderate insider selling. Any failure to meet aggressive growth expectations could negatively impact the stock price."
     }
    }
   ]
  }
 ]
}